EcoDrugPlus

Serine (Or Cysteine) Peptidase Inhibitor, Clade C (Antithrombin), Member 1

Ensembl ID : ENSMSIG00000020371
Gene Symbol: SERPINC1
1 Cross references
214 Possible Orthologues:

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSMSIG00000005491
Gene Symbol: SIGMAR1
1 Cross references
219 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSMSIG00000023624
Gene Symbol: SMO
1 Cross references
219 Possible Orthologues:

Sodium Channel, Nonvoltage-Gated 1 Alpha

Ensembl ID : ENSMSIG00000007175
Gene Symbol: SCNN1A
1 Cross references
168 Possible Orthologues:

Sodium Channel, Nonvoltage-Gated 1 Beta

Ensembl ID : ENSMSIG00000028132
Gene Symbol: SCNN1B
1 Cross references
166 Possible Orthologues:

Sodium Channel, Nonvoltage-Gated 1 Gamma

Ensembl ID : ENSMSIG00000028117
Gene Symbol: SCNN1G
1 Cross references
170 Possible Orthologues:

Sodium Channel, Voltage-Gated, Type I, Alpha

Ensembl ID : ENSMSIG00000013713
Gene Symbol: SCN1A
1 Cross references
154 Possible Orthologues:

Sodium Channel, Voltage-Gated, Type Ii, Alpha

Ensembl ID : ENSMSIG00000014252
Gene Symbol: SCN2A
1 Cross references
139 Possible Orthologues:

Sodium Channel, Voltage-Gated, Type Iii, Alpha

Ensembl ID : ENSMSIG00000014515
Gene Symbol: SCN3A
1 Cross references
176 Possible Orthologues:

Sodium Channel, Voltage-Gated, Type Iv, Alpha

Ensembl ID : ENSMSIG00000024972
Gene Symbol: SCN4A
1 Cross references
203 Possible Orthologues:

Sodium Channel, Voltage-Gated, Type Ix, Alpha

Ensembl ID : ENSMSIG00000013374
Gene Symbol: SCN9A
1 Cross references
125 Possible Orthologues:

Sodium Channel, Voltage-Gated, Type V, Alpha

Ensembl ID : ENSMSIG00000003219
Gene Symbol: SCN5A
1 Cross references
109 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).